How the heart can fibrillate: when diversity is a disadvantage.
Ralph
R
Lazzara
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000503:physiopathology; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology*; D002722:Chlorobenzenes; D004195:Disease Models, Animal; D004285:Dogs; D006801:Humans; D008012:Lidocaine / Q000494:pharmacology; D011802:Quinidine / Q000494:pharmacology; D062367:ortho-Aminobenzoates / Q000494:pharmacology*
C517140:2-(4-(2-(3,4-dichlorophenyl)ethyl)phenylamino)benzoic acid; D000889:Anti-Arrhythmia Agents; D002722:Chlorobenzenes; D062367:ortho-Aminobenzoates; D008012:Lidocaine; D011802:Quinidine